Behavioural Pharmacology · 1997 · 53 citations · 0 references
MedicineBehavioral SciencesPharmacologyBehavioral PharmacologyNeuropharmacologyPsychopharmacologyAggressionAntidepressant PharmacologyAntidepressant PharmacotherapyAntidepressant TherapyPsychostimulant PharmacologySerotonergic Pharmacology5-Hydroxytryptamine 1A Receptor Agonists5-Hydroxytryptamine Receptor PharmacologyAgonistic BehaviorAntidepressant EfficacyAntidepressant MedicationsAntidepressant ResponsePharmacodynamic MechanismsSerotonergic Mechanisms
Acute and chronic antidepressant drug treatments respectively decrease and increase the aggressive behaviour of resident rats during encounters with unfamiliar conspecifics. We have now examined the effect of the 5-hydroxytryptamine1A receptor antagonist, WAY-100635, on fluoxetine-, paroxetine- or venlafaxine-induced changes in aggression. WAY-100635 (0.1 mg/kg), which did not modify behaviour when given alone, potentiated the venlafaxine (5.54 mg/kg)-induced reduction in aggression after acute treatment and, during chronic treatment, accelerated the fluoxetine (0.34 mg/kg/day)-induced increase in aggression, from day 5 to day 2. A similar change in time course was seen with paroxetine (0.33 mg/kg/day), although the increase in aggression was smaller. Venlafaxine (5.54 mg/kg/day, alone or co-administered with WAY-100635) increased aggression by day 2. During chronic treatment, therefore, venlafaxine, at the dose used, had a more rapid onset of action than either fluoxetine or paroxetine, whereas the fluoxetine- and paroxetine-, but not the venlafaxine-, induced increase in aggression was accelerated by WAY-100635. These studies further support the hypothesis that selective blockade of the 5-hydroxytryptamine1A receptor augments the effects of antidepressant drugs in an animal model predictive of antidepressant activity, presumably by concomitant blockade of the somatodendritic 5-hydroxytryptamine1A autoreceptor-mediated negative feedback system of serotonergic neurones.